Yes, IgM is typically low in multiple myeloma. The suppression of normal immunoglobulins, including IgM, is one of the hallmark features of the disease and affects the vast majority of patients. This phenomenon, called immunoparesis, means the cancerous plasma cells crowd out and interfere with the normal immune cells that would otherwise produce protective antibodies like IgM.
Why Myeloma Drives IgM Down
In a healthy immune system, plasma cells produce a balanced mix of antibody types: IgG, IgA, and IgM. In multiple myeloma, one clone of plasma cells multiplies out of control and pumps out massive quantities of a single abnormal protein (the M-protein), while production of all other normal antibodies drops sharply.
The suppression happens through several overlapping mechanisms. Myeloma cells alter the bone marrow environment in ways that directly inhibit normal B cells and plasma cells. They increase levels of growth-inhibiting signals while decreasing the stimulatory signals that healthy immune cells need. Shifts in T-cell populations also play a role: patients show higher numbers of suppressor T cells and fewer helper T cells, which tilts the balance away from normal antibody production.
One recently studied mechanism involves a protein called BCMA, which sits on the surface of both normal and malignant plasma cells. Normally, BCMA helps plasma cells survive and produce antibodies when it binds to signaling molecules in the bone marrow. But myeloma cells shed a soluble form of BCMA into the bloodstream. This soluble fragment acts as a decoy, intercepting the signaling molecules before they can reach normal plasma cells. Without those survival signals, healthy plasma cells can’t mature or produce immunoglobulins properly, and IgM production falls.
How Myeloma Subtype Affects IgM Levels
About 70% of myeloma cases produce an IgG M-protein, with IgA myeloma being the next most common. In both of these subtypes, IgM is one of the “uninvolved” immunoglobulins that gets suppressed. IgA myeloma tends to cause more aggressive suppression of uninvolved immunoglobulins than IgG myeloma. In MGUS (the precursor condition), IgA cases show uninvolved immunoglobulin suppression about 33% of the time, compared to only 5% for IgG cases. By the time the disease has progressed to active myeloma, suppression rates are substantially higher across all subtypes.
Patients with light chain only myeloma, where the cancerous cells produce only antibody fragments rather than a complete immunoglobulin, also develop severe immunoparesis. Higher M-protein levels at diagnosis are associated with more pronounced drops in all polyclonal immunoglobulins, including IgM.
Low IgM as a Prognostic Marker
The degree of IgM suppression at diagnosis carries prognostic weight. Patients with the most severe IgM immunoparesis tend to have the poorest survival outcomes. This makes sense intuitively: deeper suppression of normal antibodies reflects a larger, more dominant malignant clone that has more thoroughly displaced healthy immune function.
IgM suppression also matters earlier in the disease spectrum. In patients with MGUS, low IgM is a statistically significant risk factor for progression to active myeloma. In one study, 14 out of 18 patients whose MGUS progressed had either general immunoglobulin suppression or specific IgM suppression. Monitoring IgM levels over time can help identify which MGUS patients are at higher risk of developing full-blown myeloma.
Infection Risk From Low IgM
IgM antibodies are your body’s first responders to new infections. They’re particularly important for fighting bacterial infections, especially encapsulated bacteria like pneumococcus and Haemophilus. When IgM drops, your ability to mount an early immune defense weakens significantly. This is a major reason why infections are one of the leading causes of illness and death in myeloma patients, particularly in the first few months after diagnosis when immunoparesis is often at its worst and treatment has not yet restored any immune function.
Whether IgM Recovers With Treatment
Successful treatment of myeloma can allow IgM levels to recover, but the timeline depends on the type of therapy. After autologous stem cell transplant, IgM levels in patients who don’t receive additional B-cell-depleting therapies can normalize by about three months post-transplant. However, certain additional treatments can delay this recovery significantly. The restoration of normal immunoglobulin levels is considered a positive sign and is sometimes used as one indicator that the immune system is rebuilding after treatment.
Recovery of IgM is not guaranteed, especially in patients with relapsed or refractory disease. Ongoing treatment cycles can continue to suppress normal antibody production, and some patients require immunoglobulin replacement therapy to maintain adequate antibody levels and reduce infection risk.
When IgM Is High Instead: A Different Diagnosis
There is one important exception to the rule that plasma cell cancers cause low IgM. Waldenström macroglobulinemia is a condition where the malignant cells actually produce IgM as their M-protein, resulting in very high IgM levels. This is a fundamentally different disease from typical multiple myeloma, though the two can occasionally be confused. Waldenström macroglobulinemia involves lymphoplasmacytic cells (a hybrid of lymphocytes and plasma cells) rather than the purely plasmacytic cells seen in myeloma. It also typically lacks the lytic bone lesions that characterize myeloma.
True IgM myeloma, where malignant plasma cells produce an IgM M-protein, is extremely rare. A large study of patients with IgM paraproteins found that Waldenström macroglobulinemia accounted for roughly 60% of cases, while not a single patient was diagnosed with IgM myeloma. When IgM myeloma is suspected, the diagnosis requires bone marrow with at least 10% plasma cells along with lytic bone lesions or specific chromosomal abnormalities to distinguish it from Waldenström macroglobulinemia.